Edwards Lifesciences (EW) announced that it has executed an accelerated share repurchase agreement repurchase $500M of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800M of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately 5M shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be based on the volume weighted average share price during the term of the agreement. The company is funding the share repurchase under the ASR with its existing cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences’ TRISCEND II Trial: A Game-Changer in Tricuspid Valve Treatment?
- Edwards Lifesciences’ ENCIRCLE Trial: A New Hope for Mitral Regurgitation Patients
- Edwards Lifesciences’ TRISCEND Study: A Game-Changer in Tricuspid Valve Replacement?
- Edwards Lifesciences Advances with SAPIEN X4 Heart Valve Study
- Hold Rating for Edwards Lifesciences Amid Uncertainty in JenaValve Deal and Adjusted EPS Guidance